Idiopathic Pulmonary Fibrosis Market Size stood at USD 2.88 billion in 2020 and over the forecast period, the market will register 4.01% CAGR. The market shares across drug types including Pirfenidone, Nintedanib, Generic Pirfenidone, Pamrevlumab, mechanism of action including Anti-Fibrotic Agent, Tyrosine kinase inhibitor, CGTF inhibitor and others.
Idiopathic Pulmonary Fibrosis Market Report Highlights-
Approved Drugs for Idiopathic Pulmonary Fibrosis- Esbriet (Roche) and Ofev (Boehringer Ingelheim)
Pipeline Candidates for Idiopathic Pulmonary Fibrosis- Phase 3 (Ziritaxestat, Pamrevlumab); Phase 2 (PRM-151, GB0139, Fezagepras, CC-90001)
Developments likely to impact the industry
Idiopathic Pulmonary Fibrosis Market Size Outlook
Idiopathic Pulmonary Fibrosis Market Analysis, 2021
Growing awareness about Idiotic pulmonary fibrosis (IPF), increasing prevalence of the condition, ageing and changing lifestyles coupled with smoking habits and absence of reversal treatment for IPF are encouraging companies to invest significantly in R&D to gain from the huge unmet demand. Companies like Gilead Sciences, Fibrogen, Promedior, Galecto, Liminal BioSciences, Celgene Corp and others are focusing on constantly assessing diverse mechanism of actions to identify potential treatment options.
IPF is a progressive, irreversible and ultimately fatal disease characterized by progressive loss of lung function due to fibrosis, or scarring, in the lungs. The condition causes shortness of breath, and a deterioration in lung function and exercise tolerance. The median survival time from diagnosis is two to three years. It typically occurs in patients over the age of 45, and tends to affect slightly more men than women. IPF is associated with increasing cough and dyspnea, greatly impacting patient quality of life and eventually leading to death from respiratory failure or complicating comorbidities.
The global Idiopathic Pulmonary Fibrosis market is valued at $2,878 million in 2020. Further, over the forecast period to 2028, the market is poised to register 4.01% growth (Compounded Annual Growth Rate- CAGR) to reach $3,942 million in 2028. The major factors shaping up the demand outlook include increasing incidences of disease, expiry of Esbriet patent, launch of generics, and possible approval of Pamrevlumab. On the other hand, low penetration rate in developing markets, low awareness and affordability in these markets, unknown etiology of the condition, and inadequate and difficult diagnosis are main market challenges.
The report analyses the global Idiopathic Pulmonary Fibrosis market across drug types, mechanism of actions and geographies. The drug types analysed in the report include Pirfenidone, Nintedanib, Generic Pirfenidone and Pamrevlumab. Among types, Nintedanib remain the dominant drug type with 54.5% market share.
In terms of mechanism of action, the market is categorized into Anti-Fibrotic Agents, Tyrosine kinase inhibitor, and CGTF inhibitor. Of these Tyrosine kinase inhibitor dominated the industry in terms of market size with 54.6% market share.
High awareness and affordability coupled with increasing prevalence of the disease are the main market drivers for Idiopathic Pulmonary Fibrosis in developed countries in North America, and Europe. Among regions, North America remained the global markets with the US being the world’s largest country for IPF treatment. The region accounted for 70.9% of global market demand, followed by Europe (21%). On the other hand, Asia Pacific is the fastest growing geography, forecast to register 7.99% CAGR over the forecast period. The fastest growth in China, India, South Korea, Brazil, Russia and other countries is driven by launch of generics and availability of Pamrevlumab in the second half of forecast period.
In terms of companies, the current market landscape is characterized by presence of only two companies- Boehringer Ingelheim and F. Hoffman La Roche.
Idiopathic Pulmonary Fibrosis Market Trends- Small companies offer potential investment and partnership opportunities
Small and medium size companies developing late stage pipeline therapeutic candidates for IPF seek out potential investors, federal funding, or strategic partnering with larger and mature companies in the form of licensee or through strategic alliances.
Esbriet was originally developed by InterMune (a Brisbane, California based biotechnology company) and it reached definitive merger agreement with Roche in August 2014.
Similarly, in February 2020, Promedior, Inc (developing PRM 151) announced the successful completion of its previously announced sale to Roche
Galecto Biotech and PharmAkea, two clinical-stage pharmaceutical companies with robust pipelines in fibrotic diseases have merged into single company- Galecto. The emerging company continues to focus on TD139/ GB0139.
Idiopathic Pulmonary Fibrosis Market Drivers- Idiopathic Pulmonary Fibrosis (IPF) has Strong Unmet Demand
IPF presents significant unmet demand potential. As both the approved drugs do not improve fatal prognosis of IPF but instead slows the progression, there exists huge unmet market demand.
Further, high rate of treatment discontinuation and also presents side effects such as gastrointestinal side effects, liver problems, nausea and vomiting, diarrhea, weight loss, high blood pressure and others.
Companies often use six-minute walking test (6 MWT) as one of the standard tests to obtain acceptance by physicians and patients. Pharmaceutical companies and institutes are investing in developing a drug that has minimal side effects and has more efficacy.
FibroGen Inc. Idiopathic Pulmonary Fibrosis Market Company Analysis
Based in San Francisco, FibroGen, Inc. is a world-class leading research-based biopharmaceutical company that engages in the discovery, development, and commercialization of the pipeline of first-in-class novel therapeutics.
The company is currently focused on developing roxadustat, or FG-4592, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development. It is used for the treatment of anemia in chronic kidney disease;
FibroGen is also developing FG-3019, a monoclonal antibody that is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage.
Key R&D product pipeline:
Roxadustat is also in clinical trials and is an oral small molecule inhibitor of HIF prolyl hydroxylase (“HIF-PH”) activity that has received New Drug Application (“NDA”) approval in anemia associated with chronic kidney disease (“CKD”) in dialysis-dependent (“DD”) patients from the National Medical Products Administration (“NMPA”) (previously known as the China Food and Drug Administration) of the People’s Republic of China (“China”).
Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), Duchenne muscular dystrophy (DMD), and coronavirus (COVID-19).
The company was founded in 1993 and is headquartered in San Francisco, CA.
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures 7
2. EXECUTIVE SUMMARY 9
2.1 Summary 9
2.1.1 Overview 9
2.1.2 Market Sales 10
2.1.3 Approved Drugs 10
2.1.4 Pipeline Candidates 11
2.1.5 Developments likely to impact the industry 11
2.2 Idiopathic Pulmonary Fibrosis Industry Outlook, 2020 – 2028 12
2.3 Abbreviations 13
3. INTRODUCTION TO IDIOPATHIC PULMONARY FIBROSIS MARKET 14
3.1 Market Segments - Types, Applications, and Countries 14
3.2 Report Guide 15
3.3 Research Methodology 16
4. MACROECONOMIC & DEMOGRAPHIC OUTLOOK 17
4.1 GDP Outlook, 2020 – 2030 17
4.2 Population Outlook of Select Countries, 2020 – 2030 18
5. OVERVIEW OF THE IDIOPATHIC PULMONARY FIBROSIS MARKET 19
5.1 Industry Panorama 19
5.2 Major Companies 21
5.3 Market Trends 21
5.3.1 Small companies offer potential investment and partnership opportunities 22
5.3.2 IPF has Strong Unmet Demand 22
5.3.3 Companies assessing diverse mechanism of actions 23
5.3.4 Special status for pipeline candidates 23
5.3.5 Unknown etiology poses challenges for new product development 23
5.3.6 Inadequate and difficult diagnosis challenges prevalence estimation in developing countries 25
5.3.7 Increasing global Healthcare Expenditure worldwide is among the main market drivers 26
5.4 Leading Drug Types 27
5.4.1 Pirfenidone (Esbriet) 28
5.4.2 Nintedanib (Ofev) 30
5.4.3 Others 31
5.5 Dominant Mechanism of Action 34
5.5.1 Anti-Fibrotic Agents 35
5.5.2 Tyrosine kinase inhibitor 36
5.5.3 Others 37
5.6 Regional Outlook 38
6. GLOBAL OUTLOOK ACROSS COVID-19 SCENARIOS 40
6.1 Post COVID Scenario 40
6.2 Pre COVID Scenario 41
7. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET ANALYSIS 42
7.1 Overview 42
7.1.1 The US dominates the North American Idiopathic Pulmonary Fibrosis Market 43
7.3 Market Outlook by Country 44
7.3.1 The US 44
7.3.2 Other North America 45
8. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET ANALYSIS 46
8.1 Overview 46
8.1.1 Germany dominates the European Idiopathic Pulmonary Fibrosis Market 47
8.2 Market Outlook by Country 48
8.2.1 Germany 48
8.2.2 United Kingdom 49
8.2.3 France 50
8.2.4 Spain 51
8.2.5 Italy 52
8.2.6 Other Europe 53
9. ASIA PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET ANALYSIS 54
9.1 Overview 54
9.1.1 China dominates the Asia Pacific Idiopathic Pulmonary Fibrosis Market 55
9.2 Market Outlook by Country 56
9.2.1 Japan 56
9.2.2 Other Asia Pacific 57
10. REST OF WORLD IDIOPATHIC PULMONARY FIBROSIS MARKET ANALYSIS 58
10.1 Overview 58
11. COMPETITIVE LANDSCAPE 59
11.1 Boehringer Ingelheim GmbH 59
11.1.1 Overview 59
11.1.2 SWOT Analysis 62
11.2 FibroGen Inc 65
11.2.1 Overview 65
11.2.2 SWOT Analysis 66
11.2.3 Key Financials 69
11.3 Liminal Biosciences Inc 72
11.3.1 Overview 72
11.3.2 SWOT Analysis 74
11.3.3 Key Financials 76
11.4 Medicinova Inc 79
11.4.1 Overview 79
11.4.2 SWOT Analysis 81
11.4.3 Key Financials 83
11.5 F. Hoffmann-LA Roche 86
11.5.1 Overview 86
11.5.2 SWOT Analysis 88
11.5.3 Key Financials 90
12. LATEST DEVELOPMENTS 93
12.1 Stem Cell Study into Repairing Damaged Lungs Wins $100K ALA Grant 93
12.2 Gilead's $5B Galapagos black hole widens as pair tosses out phase 3 asset after flop 95
12.3 Paragonix Announces First-in-Man use of LUNGguard Donor Lung Preservation System by Duke Hospital 97
12.4 Avalyn Pharma Reports Update in Ongoing Idiopathic Pulmonary Fibrosis Trial 99
12.5 Galecto, Inc. Receives U.S. and EU Orphan Drug Designations for GB0139 in Idiopathic Pulmonary Fibrosis 100
12.6 First Patient Enrolls In PRECISIONS Study For Treatment Of Idiopathic Pulmonary Fibrosis 101
12.7 Targeted therapies developed to reduce lung fibrosis 102
12.8 Genkyotex Announces the Enrollment of the 1st Patient in the Phase 2 Trial of Setanaxib in Idiopathic Pulmonary Fibrosis (IPF) 103
13. APPENDIX 105
13.1 About USD Analytics 105
13.2 Sources and Research Methodology 105
13.3 Copyright and Disclaimer 106